Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an announcement.
Recce Pharmaceuticals Ltd has announced the cessation of 8,754,423 performance shares due to a selective buy-back, effective October 7, 2025. This move may impact the company’s capital structure and could be part of a strategic effort to optimize shareholder value and streamline operations, signaling potential shifts in their market positioning.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the development of new classes of synthetic anti-infectives. Their primary products include innovative treatments targeting a broad spectrum of infectious diseases, with a market focus on addressing antibiotic-resistant infections.
Average Trading Volume: 113,112
Technical Sentiment Signal: Hold
Current Market Cap: A$127.2M
For a thorough assessment of RCE stock, go to TipRanks’ Stock Analysis page.